Inimmune, a biotechnology company developing immune therapies and components for more effective vaccines, announced that it has raised $22 million Series A funding led by Two Bear Capital. With this investment, Two Bear Capital’s Founder and Managing Partner Michael Goguen will join Inimmune’s board of directors. “We are excited to partner with Two Bear Capital…